Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06743126 · ClinicalTrials.gov registry record · Phase 3
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
A Phase 3 study of Melanoma, Cutaneous Malignant, sponsored by Immatics US.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT06743126 is a Phase 3 study of Melanoma, Cutaneous Malignant that is actively recruiting participants, run by Immatics US. The registered enrollment target is 360 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT06743126, a Phase 3 study of Melanoma, Cutaneous Malignant, is actively recruiting participants, sponsored by Immatics US.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma. For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/
Conditions Studied
Interventions
- BIOLOGICAL pembrolizumab
- BIOLOGICAL IMA203
- BIOLOGICAL nivolumab plus relatlimab
- BIOLOGICAL lifileucel
- BIOLOGICAL nivolumab
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- UC San Diego Moores Cancer Center - La Jolla
- UCLA Hematology/Oncology - Los Angeles
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
- Stanford Cancer Center - Stanford
Florida
- Mayo Clinic Florida - Jacksonville
- University of Miami - Sylvester Comprehensive Cancer Cente - Miami
- Moffitt Cancer Center - Tampa
Arizona
- Mayo Clinic - Phoenix
- Honor Health Research Institute - Scottsdale
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Colorado
- The University of Colorado, Anschutz Medical Campus - Aurora
Connecticut
- Yale Cancer Center - New Haven
Illinois
- University of Chicago Medical Center - Chicago
Maryland
- University of MD Greenebaum Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2025-01-14 |
| Est. Completion | 2031-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06743126
The ClinicalTrials.gov registry entry for NCT06743126 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immatics US, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma, Cutaneous Malignant appearing as the primary indexed condition, and to 5 interventions - of which pembrolizumab is the first listed.
NCT06743126 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06743126 about?
NCT06743126 is a clinical study titled "SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma". This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in p...
What is the current status of trial NCT06743126?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2025-01-14. Estimated completion is 2031-10.
What conditions does trial NCT06743126 study?
This clinical trial studies the following conditions: Melanoma, Cutaneous Malignant.
What interventions are being tested in trial NCT06743126?
The interventions under investigation include: pembrolizumab (BIOLOGICAL), IMA203 (BIOLOGICAL), nivolumab plus relatlimab (BIOLOGICAL), lifileucel (BIOLOGICAL), nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06743126?
This trial is sponsored by Immatics US, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06743126 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.